Asia Pacific Cell Counting Market Overview
Asia Pacific Cell Counting Market Size was valued at USD 1.98 Billion in 2023. The Global Asia Pacific Cell Counting industry is projected to grow from USD 2.16 Billion in 2024 to USD 4.47 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.67% during the forecast period (2024 - 2032). Cell counting is a type of method which is used for the counting or similar quantification of cells in the life sciences, including medical diagnosis and treatment of chronic diseases such as cancer.
Increase in the number of White Blood Cells (WBC) may indicate the possibility of cancerous growth in the body. Cell counting is also important for researchers and it is one of the major steps in most experiments, which helps in maintaining cell cultures. It is an important procedure needed to be carried out before any analytical procedures and determine abnormal growth of cells. Furthermore, cell counting is an important step in many experiments done in microbiology, hematology and other medical specialties.
Drivers that increases the Asia Pacific cell counting market are emphasis of cell counting in the diagnosis and treatment of life threatening diseases such as cancer, along with a wide range of cell counting applications. For instance, according to American Cancer Society, nearly 1,688,780 new cases of cancer are expected in 2017 in the U.S., and about 600,920 deaths due to it. Furthermore, growing “out of pocket” expenditure and use of new technologies in cell counting led to market’s growth. However, high pricing of the advanced cell counting systems and lack of awareness among researchers to use advanced cell counting techniques are restraining the growth of Asia Pacific cell counting market to a certain extent.
Figure 1: Market Synopsis of Cell Counting Market by Region, 2016 (%):
Sources: National Institute of Standards & Technology, Small Business Innovation Research (SBIR), U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute Press Release, presentation, company website, annual reports, government records, journals expert interview
Asia Pacific Cell Counting Market Segmentation
The Asia Pacific cell counting market is segmented on the basis on instruments used for cell counting which are spectrophotometer, cell counter, hemocytometer, flow cytometer, hematology analyzer, microscope and other instruments.
On the basis of application of cell counting, cell structure study and cell analysis, quality control, cell viability, proliferation, signaling, identification, single cell analysis and other applications are includes.
It is also segmented on the basis of its end users which are hospitals, research institutes, pharmaceutical and biotechnology companies, clinical research organizations and other end users.
Regional Analysis of Asia Pacific Cell Counting Market
Asia Pacific cell counting market consists of countries namely China, Japan, Republic of Korea, India, Australia and rest of Asia Pacific. Increasing in number of diagnostic procedures for various chronic diseases and rising availability of cost effective diagnostic test drive the growth of the Asia Pacific cell counting market. Moreover, less complex regulations for drug development in Asian region has upsurged the growth of the Asia Pacific cell counting market.
Japan accounts the largest market share in Asia Pacific cell counting market in 2016. The growth of the Asia Pacific cell counting market is attributed to the development of medical devices in addition to research and development activities. Moreover, key market players are involved in the export of medical devices by focusing on developing markets to capture reasonable share in Asia Pacific cell counting market.
India is seen to be the fastest growing market for medical equipment manufactures. In India, the Asia Pacific cell counting market is increasing due to availability of low cost of raw material, better access to labor, increasing number of hospitals and healthcare centers. India is one of the top destinations for medical tourism, especially for orthopedic surgeries which is further influencing the market’s growth.
There is steady growth of this market in Australia and Republic of Korea during the forecast period from 2022-2030.
Key Players for Asia Pacific Cell Counting Market
Some of the key players in Asia Pacific cell counting market are:
- Bio-Rad Laboratories Inc. (U.S)
- General Electric Company (U.S)
- Agilent Technologies (U.S)
- PerkinElmer Inc. (U.S)
- Tecan Trading AG (Switzerland)
- BioTek Instruments, Inc. (U.S)
- Danaher (U.S)
- Merck KGaA (U.S)
- Thermo Fisher Scientific Inc. (U.S)
Intended Audience
- Research and development (R&D) companies
- Medical research laboratories
- Pharmaceutical companies
- Biotechnology companies
- Cell counting instruments manufacturers
- Cell counting instruments suppliers
- Academic medical institutes and universities
Report Attribute/Metric
|
Details
|
Market Size
|
USD 4.47 Billion by 2032
|
CAGR
|
9.67% (2024-2032)
|
Base Year
|
  2021
|
Forecast Period
|
  2024-2032
|
Historical Data
|
  2020
|
Forecast Units
|
 Value (USD Million)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Segments Covered
|
Types, end user, Region
|
Geographies Covered
|
Asia-Pacific
|
Key Vendors
|
Bio-Rad Laboratories Inc. (U.S), General Electric Company (U.S), Agilent Technologies (U.S), PerkinElmer Inc. (U.S), Tecan Trading AG (Switzerland), BioTek Instruments, Inc. (U.S), Danaher (U.S), and Merck KGaA (U.S), Thermo Fisher Scientific Inc. (U.S)
|
Asia Pacific Cell Counting Market Highlights: